Point of Care Molecular Diagnostics Market Overview
The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2%. This growth is attributed to the increasing incidence of infectious diseases, rising awareness among patients and healthcare professionals, technological advancements in molecular diagnostics, and increasing adoption of point-of-care testing. Additionally, factors such as the growing geriatric population and rising demand for personalized medicine are expected to drive the market growth. However, high cost associated with molecular diagnostics and the lack of reimbursement policies in some countries are likely to hamper the growth of the market.
Point of Care Molecular Diagnostics Market Trends and Drivers
The Point of Care Molecular Diagnostics market is expected to witness significant growth over the forecast period. This growth can be attributed to the increasing prevalence of infectious diseases and rising demand for quick diagnosis. Growing awareness regarding the importance of early diagnosis of diseases is also driving the growth of the market. In addition, increasing investment in molecular diagnostics by governments in developing countries and rising healthcare expenditure are expected to further drive the growth of the market. Moreover, the emergence of advanced technologies such as multiplex and miniaturized assays is likely to propel the growth of the market. Furthermore, increasing research and development activities and the introduction of novel products are expected to provide significant opportunities for the growth of the market.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=143524127
Regional Point of Care Molecular Diagnostics Market Analysis
The regional point of care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America dominates the market owing to the presence of a large number of players, technological advancements, and the presence of a well-established healthcare sector. Europe is the second largest market due to the presence of sophisticated healthcare infrastructure and increasing adoption of POC molecular diagnostics. Asia Pacific is expected to witness significant growth due to the presence of huge population, increasing awareness of POC molecular diagnostics, and rising government investments in the healthcare sector. The Rest of the World is expected to witness moderate growth due to the presence of developing healthcare infrastructure and the increasing focus of market players on emerging economies.
Major Players in the Point of Care Molecular Diagnostics Market
The major players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), Quidel Corporation (US), QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), and GeneSTAT Molecular Diagnostics, LLC (US).
Impact of COVID-19 on the Point of Care Molecular Diagnostics Market
The outbreak of the coronavirus pandemic has had a major impact on the point of care molecular diagnostics market. The demand for point of care molecular diagnostics has increased drastically due to the need for rapid diagnosis and testing of COVID-19. Governments and healthcare organizations across the world have been taking various initiatives to increase the availability of point of care molecular diagnostics tests, in order to enable early diagnosis and treatment of the disease. Furthermore, the development of various molecular diagnostics tests for COVID-19 has further driven the demand for point of care molecular diagnostics. However, the pandemic has also caused disruption in the supply chain of various point of care molecular diagnostics products, due to the restrictions imposed by governments in order to contain the spread of the virus. This has hindered the growth of the point of care molecular diagnostics market.
Challenges and Opportunities in the Point of Care Molecular Diagnostics Market
The point of care (POC) molecular diagnostics market is a rapidly growing market that provides more accurate and timely diagnosis of diseases. However, there are a number of challenges and opportunities that providers and patients face when considering POC molecular diagnostics.
Challenges:
- Cost: The cost of POC molecular diagnostics tests is typically much higher than standard laboratory tests, making them less accessible for many patients.
- Availability: POC molecular diagnostics tests are not available in all locations, making them difficult to access for patients in certain areas.
- Regulatory Hurdles: Regulatory hurdles, such as the need for premarket approval from the FDA, can be difficult and time consuming for manufacturers of POC molecular diagnostics tests.
- Training and Education: There is a need for training and education for healthcare providers regarding the use of POC molecular diagnostics tests.
Opportunities:
- Increase in Demand: The demand for POC molecular diagnostics tests is expected to increase as the technology becomes more popular and accessible.
- Unmet Needs: There are a number of unmet needs in the POC molecular diagnostics market, providing opportunities for new products and services.
- Technological Advances: Technological advances, such as the development of more accurate tests, are opening up new opportunities for POC molecular diagnostics.
- Collaboration: Collaboration between healthcare providers, manufacturers, and regulatory bodies can help to facilitate the development and adoption of POC molecular diagnostics tests.
Conclusion: What is the Future of the Point of Care Molecular Diagnostics Market?
The future of the point of care molecular diagnostics market is expected to be strong in the years to come. The increasing demand for accurate, rapid and cost-effective diagnostic tests is driving the growth of the market. and chronic conditions are expected to fuel the demand for point of care molecular diagnostics. With the advent of new technological advancements, such as digital PCR and CRISPR-based diagnostics, the market is likely to witness significant growth in the near future. Collaborations between market players and rising investments in RD are expected to further accelerate the growth of the market.
Related Content Sources:
https://www.marketsandmarkets.com/PressReleases/point-of-care-molecular-diagnostic.asp
https://www.marketsandmarkets.com/ResearchInsight/point-of-care-molecular-diagnostic-market.asp
